Connexin 43 and bone: Not just a gap junction protein;Conexina 43 y hueso: No Sólo una proteína de las uniones gap

Actualizaciones en Osteologia

Volumn 7, Issue 2, 2011, Pages 79-90

  Plotkin, Lilian I ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Bone; Connexin43; Osteoblast; Osteocyte

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CONNEXIN 43; GAP JUNCTION PROTEIN; PARATHYROID HORMONE;

APOPTOSIS; CELL COMMUNICATION; CELL MEMBRANE; CELL SURVIVAL; CORTICAL BONE; IN VITRO STUDY; IN VIVO STUDY; OSTEOBLAST; OSTEOCYTE; REVIEW; SIGNAL TRANSDUCTION;

EID: 80052997381     PISSN: 16698975     EISSN: 16698983     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Doty SB. Morphological evidence of gap junctions between bone cells. Calcif Tissue Int 1981; 33:509-12.
2. Evans WH, Martin PE. Gap junctions: structure and function. Mol Membr Biol 2002; 19:121-36.
3. Goodenough DA, Paul DL. Beyond the gap: functions of unpaired connexon channels. Nat Rev Mol Cell Biol 2003; 4:285-94.
4. Giepmans BN. Gap junctions and connexin-interacting proteins. Cardiovasc Res 2004; 62:233-45.
5. Dbouk HA, Mroue RM, El-Sabban ME, Talhouk RS. Connexins: a myriad of functions extending beyond assembly of gap junction channels. Cell Commun Signal 2009; 7:4.
6. Dang X, Doble BW, Kardami E. The carboxy-tail of connexin-43 localizes to the nucleus and inhibits cell growth. Mol Cell Biochem 2003; 242:35-38.
7. Dang X, Jeyaraman M, Kardami E. Regulation of connexin-43-mediated growth inhibition by a phosphorylatable amino-acid is independent of gap junction-forming ability. Mol Cell Biochem 2006; 289:201-7.
8. Crespin S, Bechberger J, Mesnil M, Naus CC, Sin WC. The carboxy-terminal tail of connexin43 gap junction protein is sufficient to mediate cytoskeleton changes in human glioma cells. J Cell Biochem 2010; 110:589-97.
9. Palumbo C, Palazzini S, Marotti G. Morphological study of intercellular junctions during osteocyte differentiation. Bone 1990; 11:401-6.
10. Jones SJ, Gray C, Sakamaki H et al. The incidence and size of gap junctions between the bone cells in rat calvaria. Anat Embryol (Berl) 1993; 187:343-52.
11. Schirrmacher K, Schmitz I, Winterhager E et al. Characterization of gap junctions between osteoblast-like cells in culture. Calcif Tissue Int 1992; 51:285-90.
12. Civitelli R, Beyer EC, Warlow PM, Robertson AJ, Geist ST, Steinberg TH. Connexin43 mediates direct intercellular communication in human osteoblastic cell networks. J Clin Invest 1993; 91:1888-96.
13. Kato Y, Windle JJ, Koop BA, Mundy GR, Bonewald LF. Establishment of an osteocyte-like cell line, MLO-Y4. J Bone Miner Res 1997; 12:2014-23.
14. Su M, Borke JL, Donahue HJ, et al. Expression of connexin 43 in rat mandibular bone and periodontal ligament (PDL) cells during experimental tooth movement. J Dent Res 1997; 76:1357-66.
15. Ilvesaro J, Väänänen K, Tuukkanen J. Bone-resorbing osteoclasts contain gapjunctional connexin-43. J Bone Min Res 2000; 15:919-26.
16. Yellowley CE, Li Z, Zhou Z, Jacobs CR, Donahue HJ. Functional gap junctions between osteocytic and osteoblastic cells. J Bone Miner Res 2000;15:209-17.
17. Paic F, Igwe JC, Nori R et al. Identification of differentially expressed genes between osteoblasts and osteocytes. Bone 2009; 45:682-92.
18. Lecanda F, Towler DA, Ziambaras K et al. Gap junctional communication modulates gene expression in osteoblastic cells. Mol Biol Cell 1998; 9:2249-58.
19. Upham BL, Suzuki J, Chen G et al. Reduced gap junctional intercellular communication and altered biological effects in mouse osteoblast and rat liver oval cell lines transfected with dominantnegative connexin 43. Mol Carcinog 2003; 37:192-201.
20. Ilvesaro J, Tavi P, Tuukkanen J. Connexinmimetic peptide Gap 27 decreases osteoclastic activity. BMC Musculoskelet Disord 2001; 2:10.
21. Ransjo M, Sahli J, Lie A. Expression of connexin 43 mRNA in microisolated murine osteoclasts and regulation of bone resorption in vitro by gap junction inhibitors. Biochem Biophys Res Commun 2003; 303:1179-85.
22. Schilling AF, Filke S, Lange T et al. Gap junctional communication in human osteoclasts in vitro and in vivo. J Cell Mol Med 2008; 12:2497-504.
23. Reaume AG, de Sousa PA, Kulkarni S et al. Cardiac malformation in neonatal mice lacking connexin43. Science 1995; 267:1831-34.
24. Lecanda F, Warlow PM, Sheikh S, Furlan F, Steinberg TH, Civitelli R. Connexin43 deficiency causes delayed ossification, craniofacial abnormalities, and osteoblast dysfunction. J Cell Biol 2000; 151:931-44.
25. Thi MM, Urban-Maldonado M, Spray DC, Suadicani SO. Characterization of human telomerase reverse transcriptase (hTERT) immortalized osteoblast cell lines generated from wildtype and connexin43- null mouse calvaria. Am J Physiol Cell Physiol 2010; 299:C994-C1006.
26. Roscoe W, Veitch GI, Gong XQ et al. Oculodentodigital dysplasia-causing connexin43 mutants are non-functional and exhibit dominant effects on wild-type connexin43. J Biol Chem 2005; 280: 11458-66.
27. Dobrowolski R, Sasse P, Schrickel JW et al. The conditional connexin43G138R mouse mutant represents a new model of hereditary oculodentodigital dysplasia in humans. Hum Mol Genet 2008; 17:539-54.
28. Flenniken AM, Osborne LR, Anderson N et al. A Gja1 missense mutation in a mouse model of oculodentodigital dysplasia. Development 2005; 132:4375-86.
29. Watkins M, Ornitz D, Willecke K, Civitelli R. Connexin43 is required for normal skeletal development and bone mass acquisition. J Bone Min Res 2006; 21:S56.
30. Chung D, Castro CH, Watkins M et al. Low peak bone mass and attenuated anabolic response to parathyroid hormone in mice with an osteoblast-specific deletion of connexin43. J Cell Sci 2006; 119:4187-98.
31. Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T. Connexin 43 is required for the antiapoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res 2008; 23:1712-21.
32. McLachlan E, Plante I, Shao Q et al. ODDD-Linked Cx43 Mutants Reduce Endogenous Cx43 Expression and Function in Osteoblasts and Inhibit Late Stage Differentiation. J Bone Miner Res 2008; 23:928-38.
33. Plotkin LI, Manolagas SC, Bellido T. Transduction of cell survival signals by connexin-43 hemichannels. J Biol Chem 2002; 277:8648-57.
34. Romanello M, D'Andrea P. Dual mechanism of intercellular communication in HOBIT osteoblastic cells: a role for gapjunctional hemichannels. J Bone Miner Res 2001; 16:1465-76.
35. Cherian PP, Siller-Jackson AJ, Gu S et al. Mechanical strain opens connexin 43 hemichannels in osteocytes: a novel mechanism for the release of prostaglandin. Mol Biol Cell 2005; 16:3100-3106.
36. Li H, Liu TF, Lazrak A et al. Properties and regulation of gap junctional hemichannels in the plasma membranes of cultured cells. J Cell Biol 1996; 134:1019-30.
37. John SA, Kondo R, Wang SY, Goldhaber JI, Weiss JN. Connexin-43 hemichannels opened by metabolic inhibition. J Biol Chem 1999; 274:236-40.
38. Quist AP, Rhee SK, Lin H, Lal R. Physiological role of gap-junctional hemichannels. Extracellular calciumdependent isosmotic volume regulation. J Cell Biol 2000; 148:1063-74.
39. Kamermans M, Fahrenfort I, Schultz K, Janssen-Bienhold U, Sjoerdsma T, Weiler R. Hemichannel-mediated inhibition in the outer retina. Science 2001;292:1178-80.
40. Bivi N, Lezcano V, Romanello M, Bellido T, Plotkin LI. Connexin43 interacts with β- arrestin: a pre-requisite for osteoblast survival induced by parathyroid hormone. J Cell Biochem 2011; DOI 10.1002/jcb.23208.
41. Benini S, Perbal B, Zambelli D, et al. In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene 2005; 24:4349-61.
42. Brigstock DR. The CCN family: a new stimulus package. J Endocrinol 2003; 178:169-75.
43. Gupta N, Wang H, McLeod TL et al. Inhibition of glioma cell growth and tumorigenic potential by CCN3 (NOV). Mol Pathol 2001; 54:293-99.
44. Rydziel S, Stadmeyer L, Zanotti S, Durant D, Smerdel-Ramoya A, Canalis E. Nephroblastoma overexpressed (NOV) inhibits osteoblastogenesis and causes osteopenia. J Biol Chem 2007; 282:19762-72.
45. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104:1363-74.
46. Rogers MJ. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 2004; 75:451-61.
47. Hughes DE, Wright KR, Uy HL et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Min Res 1995; 10:1478-87.
48. Kogianni G, Mann V, Ebetino F, et al. Fas/CD95 is associated with glucocorticoidinduced osteocyte apoptosis. Life Sci 2004; 75:2879-95.
49. Plotkin LI, Manolagas SC, Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/ osteocytes with novel analogs. Bone 2006; 39:443-52.
50. Plotkin LI, Bivi N, Bellido T. A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice. Bone 2011; 49:122-27.
51. Dunford JE, Thompson K, Coxon FP et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001; 296:235-42.
52. Brown RJ, Van Beek E, Watts DJ, Lowik CW, Papapoulos SE. Differential effects of aminosubstituted analogs of hydroxy bisphosphonates on the growth of Dictyostelium discoideum. J Bone Min Res 1998; 13:253-58.
53. Van Beek E, Lowik C, Que I, Papapoulos S. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. J Bone Min Res 1996; 11:1492-97.
54. Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of ERK activation. J Biol Chem 2005; 280:7317-25.
55. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science 2005; 308:512-17.
56. DeFea KA, Zalevsky J, Thoma MS, Dery O, Mullins RD, Bunnett NW. Beta-arrestindependent endocytosis of proteinaseactivated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol 2000; 148:1267-81.
57. Tohgo A, Choy EW, Gesty-Palmer D et al. The stability of the G protein-coupled receptor-β-arrestin interaction determines the mechanism and functional consequence of ERK activation. J Biol Chem 2003; 278:6258-67.
58. Ge L, Ly Y, Hollenberg MD, DeFea K. A beta-arrestin-dependent scaffold is associated with prolonged MAPK activation in pseudopodia during proteaseactivated receptor-2 induced chemotaxis. J Biol Chem 2003; 278:34418-26.
59. Krupnick JG, Santini F, Gagnon AW, Keen JH, Benovic JL. Modulation of the arrestin-clathrin interaction in cells. Characterization of β-arrestin dominantnegative mutants. J Biol Chem 1997; 272:32507-12.
60. Cheng B, Zhao S, Luo J, Sprague E, Bonewald LF, Jiang JX. Expression of functional gap junctions and regulation by fluid flow in osteocyte-like MLO-Y4 cells. J Bone Miner Res 2001; 16:249-59.
61. Ziambaras K, Lecanda F, Steinberg TH, Civitelli R. Cyclic stretch enhances gap junctional communication between osteoblastic cells. J Bone Min Res 1998;13:218-28.
62. Robinson JA, Chatterjee-Kishore M, Yaworsky PJ et al. WNT/beta-catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem 2006;281:31720-31728.
63. Siller-Jackson AJ, Burra S, Gu S et al. Adaptation of connexin 43-hemichannel prostaglandin release to mechanical loading. J Biol Chem 2008;283:26374-82.
64. Li J, Burr DB, Turner CH. Suppression of prostaglandin synthesis with NS-398 has different effects on endocortical and periosteal bone formation induced by mechanical loading. Calcif Tissue Int 2002;70:320-329.
65. Chambers TJ, Chow JW, Fox SW, Jagger CJ, Lean JM. The role of prostaglandins and nitric oxide in the response of bone to mechanical stimulation. Adv Exp Med Biol 1997;433:295-98.
66. Forwood MR. Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. J Bone Miner Res 1996;11:1688-93.
67. Genetos DC, Kephart CJ, Zhang Y, Yellowley CE, Donahue HJ. Oscillating fluid flow activation of gap junction hemichannels induces ATP release from MLO-Y4 osteocytes. J Cell Physiol 2007; 212:207-14.
68. Grimston SK, Brodt MD, Silva MJ, Civitelli R. Attenuated response to in vivo mechanical loading in mice with conditional osteoblast ablation of the Connexin43 gene (Gja1). J Bone Miner Res 2008; 23:879-86.
69. Rubin MR, Cosman F, Lindsay R, Bilezikian JP. The anabolic effects of parathyroid hormone. Osteoporos Int 2002;13:267-77.
70. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007;40:1434-46.
71. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999;104:439-46.
72. Miao D, He B, Jiang Y et al. Osteoblastderived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest 2005;115:2402-11.
73. Martin TJ. Osteoblast-derived PTHrP is a physiological regulator of bone formation. J Clin Invest 2005;115:2322-24.
74. Calvi LM, Sims NA, Hunzelman JL et al. Activated parathyroid hormone/ parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest 2001;107:277-86.
75. Yamamoto T, Kambe F, Cao X, Lu X, Ishiguro N, Seo H. Parathyroid hormone activates phosphoinositide 3-kinase-Akt- Bad cascade in osteoblast-like cells. Bone 2007;40:354-59.
76. Bellido T, Ali AA, Plotkin LI et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 2003; 278:50259-72.
77. Tobimatsu T, Kaji H, Sowa H et al. Parathyroid hormone increases betacatenin levels through Smad3 in mouse osteoblastic cells. Endocrinology 2006; 147:2583-90.
78. Vander Molen MA, Rubin CT, McLeod KJ, McCauley LK, Donahue HJ. Gap junctional intercellular communication contributes to hormonal responsiveness in osteoblastic networks. J Biol Chem 1996;271:12165-71.
79. Castro CHM, Stains JP, Civitelli R. The Anabolic Response to Intermittent PTH (1- 34) Requires Connexin43 (Cx43) Mediated Gap Junctional Communication. J Bone Min Res 2003;18:S100.
80. Evans WH, De Vuyst E., Leybaert L. The gap junction cellular internet: connexin hemichannels enter the signalling limelight. Biochem J 2006;397:1-14.
81. Jiang JX, Gu S. Gap junction-and hemichannel-independent actions of connexins. Biochim Biophys Acta 2005;1711:208-14.
82. Liu L, Li Y, Lin J et al. Connexin43 interacts with Caveolin-3 in the heart. Mol Biol Rep 2010;37:1685-91.
83. Butkevich E, Hulsmann S, Wenzel D, Shirao T, Duden R, Majoul I. Drebrin is a novel connexin-43 binding partner that links gap junctions to the submembrane cytoskeleton. Curr Biol 2004;14:650-658.
84. Niger C, Hebert C, Stains JP. Interaction of connexin43 and protein kinase C-delta during FGF2 signaling. BMC Biochem 2010;11:14.
85. Davy A, Bush JO, Soriano P. Inhibition of Gap Junction Communication at Ectopic Eph/ephrin Boundaries Underlies Cran iofrontonasal Syndrome. PLoS Biol 2006;4:1763-76.
86. Girao H, Catarino S, Pereira P. Eps15 interacts with ubiquitinated Cx43 and mediates its internalization. Exp Cell Res 2009;315:3587-97.
87. Li X, Su V, Kurata WE, Jin C, Lau AF. A novel connexin43-interacting protein, CIP75, which belongs to the UbL-UBA protein family, regulates the turnover of connexin43. J Biol Chem 2008;283:5748-59.
88. Park DJ, Freitas TA, Wallick CJ, Guyette CV, Warn-Cramer BJ. Molecular dynamics and in vitro analysis of Connexin43: A new 14-3-3 mode-1 interacting protein. Protein Sci 2006;15:2344-55.
89. Plotkin LI, Vyas K, Gortazar AR, Manolagas SC, Bellido T. β-arrestin complexes with connexin (Cx) 43 and anchors ERKs outside the nucleus: a requirement for the Cx43/ERK-mediated anti-apoptotic effect of bisphosphonates in osteocytes. J Bone Miner Res 2006; 21:S65.